Apr 25,2023

Clinical ink Announces New Continuous Glucose Monitoring Solution

Clinical ink, a global life science technology company, now offers continuous glucose monitoring (CGM) within its integrated digital biomarker solution. The new modules enable remote collection, central storage, and analysis of sensor data from commercially available devices for use in diabetes clinical trials.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Apr 25,2023

Conifer Health Solutions and Welldoc Enter Strategic Partnership to Launch Conifer Connect, Personalized Digital Health App Enabling Collaborative Care and Better Health

Conifer Health Solutions, a provider of Value-Based Care that helps its client organizations manage their medical spend and ensure their members successfully navigate the care continuum, and Welldoc® announced a partnership to launch Conifer Connect, a personalized digital health app designed to help members manage their daily health connected with their personal health nurse (PHN). Leveraging the Welldoc platform’s advanced AI-engine, the Conifer Connect App syncs with more than 400 smart devices, including fitness trackers and blood glucose meters, to help members track their vitals, medications, food, weight, activity, blood pressure and sleep. With the ability to aggregate these data points and identify patterns, the Conifer Connect App provides members with daily and weekly trends to help them make better health decisions and keep their PHN informed and updated on progress.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 25,2023

Insulet Announces FDA Clearance of Omnipod GO™, a First-of-its-Kind Basal-Only Insulin Pod, Further Simplifying Life for People with Type 2 Diabetes

Insulet Corporation announced the FDA clearance of its latest innovation, Omnipod GO™, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin. Omnipod GO is a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. It has been cleared for use with the following U-100 insulins: NovoLog®, Fiasp®, Humalog®, Admelog®, and Lyumjev®. The product was developed to serve people with type 2 diabetes earlier in their treatment journey by starting them on Pod therapy for their insulin delivery, rather than daily injections. Insulet plans to commercialize Omnipod GO in the United States in 2024.

REGULATORY FDA

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Apr 25,2023

Medtronic Diabetes resolves warning letter, clearing path for future innovations

Medtronic announced that the U.S. Food and Drug Administration (FDA) lifted the warning letter received at the company's Diabetes headquarters in Northridge, California, in December 2021. The resolution of the warning letter follows ongoing remediation actions from the company and proactive actions to continue to strengthen its quality systems. All regulatory restrictions associated with the warning letter have been resolved.

View Analyst & Ambassador Comments
Go to original news
Apr 24,2023

Digital Diabetes Management Market Untapped Growth Opportunities Analysis

The global digital diabetes management market is estimated to reach over USD 35.15 billion by 2030, exhibiting a CAGR of 11.16% during the forecast period, according to the publisher. The market's strong growth is primarily due to the rising incidence of diabetes and technological improvement and innovation.

#bgm

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 24,2023

ASCENSIA DIABETES CARE MARKS ONE-YEAR ANNIVERSARY OF US EVERSENSE E3 CGM LAUNCH WITH COMMERCIAL UPDATE AND INNOVATION OUTLOOK

In April 2022, Ascensia launched the Eversense® E3 CGM System for patients in the U.S., shortly after it was approved by the U.S. Food and Drug Administration (FDA). Developed by Senseonics, the system includes the longest lasting CGM sensor available, with up to six-months of wear, compared to just one or two weeks with most CGM systems. Senseonics remains responsible for research, development, innovation, and manufacturing while Ascensia is able to leverage its market-leading position in BGM to exclusively lead worldwide marketing and commercialization. Eversense CGM Systems and the Eversense CGM App are available across the US and select countries in Europe.

View Analyst & Ambassador Comments
Go to original news
Apr 21,2023

FDA Approves Medtronic MiniMed™ 780G System - World's First Insulin Pump with Meal Detection Technology* Featuring 5-Minute Auto Corrections†§

Medtronic announced U.S. FDA approval of its MiniMed™ 780G system with the Guardian™ 4 sensor requiring no fingersticks while in SmartGuard™ technology. The system provides insulin to help account for when users occasionally forget to bolus or underestimates the number of carbs in their meal. This milestone marks the approval of the only system with meal detection technology that provides automatic adjustments and corrections to sugar levels every 5 minutes

REGULATORY FDA

#closed loop

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 20,2023

Tandem Diabetes Care to Present at the BofA Securities 2023 Health Care Conference

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 4:40pm Eastern Time (1:40pm Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Apr 19,2023

Senseonics announces first pediatric 365-day CGM insertion

The insertion took place as part of the company’s ENHANCE clinical trial at the AMCR Institute. AMCR, a clinical research center, focuses on pre-diabetes, type 1, type 2 diabetes and obesity. The study operates under the direction of Dr. Timothy Bailey. Dr. Francine Kaufman, Senseonics CMO, said expanding to a pediatric population represents a “priority” for the company.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 19,2023

Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business

Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2023. In Diabetes Care, FreeStyle Libre sales were $1.2 billion, which included U.S. growth of approximately 50 percent.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES